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Introduction
 Australia’s ageing population continues to rise from 3.8 million 
aged over 65 years in 2017, to a projected 8.8 million by 2057 [1]. The 
combination of a growing ageing population, longer life expectancy 
and greater prevalence of multiple chronic diseases such as Cardio-
vascular Disease (CVD), is increasing and contributes significantly to 
the disease burden in Australia [2]. In 2017-2018, the prevalence of 
heart, stroke and vascular disease among adults increased with age, 
affecting more than 1 in 4 of those aged 75 years and over [3]. Peo-
ple with Type 2 Diabetes (T2DM) and pre-diabetes (impaired glucose 
tolerance and fasting glucose but insufficient for T2DM diagnosis) 
have also been shown to have an elevated risk of CVD [4]. CVD is 
the leading cause of death worldwide representing 31% of all deaths, 
of which 85% are due to heart attack and stroke [5]. In 2014, Ameri-
cans between 60-79 years of age and over 80 years of age have over 
70% prevalence and 80% prevalence rate of CVD respectively [6]. In 
Australia, CVD continues to be the most expensive disease burden, 
costing the government almost $8,8 billion in 2017-2018, with hospi-
tal admissions constituting more than half of that cost [7]. As the main 
risk factor for CVD is age, there is increasing interest and demand 
for research evaluating strategies that address the global burden of 
ageing. One such strategy involves investigating a drug that may have 
additional mechanisms and pathways of action to combat ageing - 
metformin.
 The aim of this review is to outline the potential benefits of met-
formin, beyond glycaemic-control to reduce the burden of ageing and 
to promote healthy ageing in healthy people without diabetes. Current 
clinical trials involving metformin will be reviewed, and the feasibil-
ity of a large Randomized Clinical Trial (RCT) to examine the role of 
metformin in primary prevention to reduce cardiovascular events in 
the healthy elderly will be discussed.
Metformin Use and its Safety
 Metformin has been successfully used for long-term treatment in 
older adults as both the first-line therapy and prevention for T2DM 
[8,9]. Metformin can be safely started at 500 mg per day and titrated 
towards the target dose of 1000 mg twice daily with eGFR is above 45 
ml/min/ 1.73m-2. Kidney function needs to be monitored in patients 
with cessation of metformin when Estimated Glomerular Filtration 
Rate (eGFR) is below 30 ml/min/ 1.73m-2 and lowering the dose to a 
maximum of 1000 mg per day if GFR stays above 30 but below 45 
ml/min/ 1.73m-2 [10,11]. In terms of serious adverse events, there is 
ongoing literature debate whether or not metformin is associated with 
lactic acidosis [12,13]. Nonetheless, the current consensus in clinical 
practice preventive guideline is to temporarily withhold metformin in 
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Abstract
 As the global ageing population rises, there is increasing in-
terest and demand for research evaluating anti-ageing strategies. 
One such strategy involves investigating a drug that may have 
additional mechanisms and pathways of action to combat ageing 
- metformin. This common glucose-lowering agent for diabetes 
has been safe, effective and globally affordable for over 60 years. 
Research into the use of metformin and its beneficial influence 
on healthy ageing is currently emerging. Although metformin’s 
effect on clinical ageing outcomes may be speculative, findings 
from studies into cellular and animal models and from observation-
al and pilot human studies support its potential beneficial effects 
on ageing. Ageing has a significant impact on the cardiovascular 
system and is the leading non-modifiable risk factor for Cardio-
vascular Disease (CVD). The incidence and prevalence of CVD 
increases with advancing age, and CVD is the leading cause of 
death for populations over 65 years of age. However, most CVD 
prevention research has focused on development of interventions 
that target “traditional” CV risk factors such as hypertension, hy-
percholesterolaemia and diabetes. Metformin has been proposed 
to be an “anti-ageing” drug, based on preclinical experiments with 
lower-order organisms and numerous retrospective data on bene-
ficial health outcomes for patients with type 2 diabetes. At present, 
randomised clinical trials to evaluate metformin’s clinical impact on 
healthy ageing are limited. Here, we review the role of metformin 
and its potential to reduce cardiovascular events in the healthy 
elderly.
Keywords: Cardiovascular risk factors; Healthy ageing; met-
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the setting of hospitalisation, acute kidney injury, and use of iodinat-
ed-contrast procedures and in the setting of acute severe illness with 
hypoxia following which metformin therapy is re-implemented [14].
Metformin and CVD
 Recently, metformin has been proposed as an anti-ageing drug 
[15]. Research into metformin’s clinical benefits beyond diabetes 
originated from the observed cardiovascular risk reduction in indi-
viduals with diabetes treated with metformin [16]. Since then, there 
is growing interest and reports regarding its potential clinical benefits 
beyond glycaemic control. Metformin has a long history of success-
ful use of as the primary drug for the prevention and treatment of 
T2DM in Australia and globally [17]. Beyond improving glycaemic 
control, metformin’s effects on clinical ageing outcomes may still be 
considered speculative, although findings from cellular and animal 
models, observational and pilot human studies support the existence 
of beneficial effects on ageing [18]. At present, progress for human 
research, using randomised clinical trials to evaluate metformin’s 
clinical impact are underway. Its use has been associated with a sig-
nificantly decreased risk of Myocardial Infarction (MI), and CVD in 
populations with T2DM taking metformin, independent of its effects 
on blood glucose level, and all-cause mortality [19]. Compared with 
other medications prescribed for T2DM treatment, metformin does 
not cause weight gain, and is generally associated with a low risk 
of hypoglycaemia [20]. People living with diabetes and pre-diabetes 
have both been shown to have an elevated risk of CVD [4], but the 
effects of metformin on CVD risk in populations without diabetes are 
unclear.
 Investigation of metformin’s mechanisms of action has gained 
traction due to the protective effects seen in both human and animal 
studies. As well as the anti-atherogenic effects of metformin [21,22], it 
has been shown to prevent diabetes-induced oxidative stress [23,24]. 
The role of metformin in preventing oxidative stress may account for 
the preventative CVD effects seen in populations with diabetes due to 
the role of diabetes-related oxidative stress in vascular tissue damage 
[25]. Metformin has been implicated in the inhibition of the Mecha-
nistic Target of Rapamycin (mTOR) signaling in monocytes pathway 
[26], reducing cardiac remodeling [27]. Metformin reduces cardio-
vascular mortality, all-cause mortality and cardiovascular events in 
Coronary Arterial Disease (CAD) patients [28]. In MI and CAD pa-
tients without T2DM, metformin has no significant effect of reducing 
the incidence of cardiovascular events, although metformin was more 
effective than sulfonylureas. Clinical evidence shown in patients with 
diabetes clearly demonstrated the therapeutic benefit of metformin in 
reducing cardiovascular mortality and morbidity in T2DM patients. 
However, there is a paucity in research investigating metformin’s 
beneficial effects in healthy older individuals without diabetes. Ex-
cept in the Diabetes Prevention Program, participants with higher 
baseline fasting glucose or glycosylated Haemoglobin (HbA1c) and 
women with a history of Gestational Diabetes Mellitus (GDM) bene-
fitted the most from a 15-year metformin intervention [29].
 A recent cohort study of older veterans with T2DM in the US 
showed that metformin reduced CVD events among individuals with 
T2DM [30]. There were CVD risk reductions by 6% among other-
wise healthy individuals, by 18% among those at risk of frailty and 
by 48% among those at high cardiovascular risk. Another recent 
large double-blind randomised, placebo-controlled trial evaluated the 
cardio-metabolic effects of metformin in adults with type 1 diabetes 
(for ≥ 5 years) and high CVD risk, showing 88% of overweight or 
obesity with an average age of 55.2 ± 8.5 years [31]. After 3 years, 
there was no difference in the primary outcome of carotid artery Inti-
ma-Media Thickness (cIMT), however there were reductions in body 
weight, LDL-cholesterol, and in atherosclerosis progression, based 
on maximal cIMT analysis. These findings highlight the potential of 
metformin for decreasing CVD risk. In a meta-analysis by Han et al., 
in MI patients and CAD patients without T2DM, metformin had no 
significant effect of reducing the incidence of cardiovascular events, 
however metformin was more effective in reducing the incidence of 
cardiovascular events than sulfonylureas [28,32,33].
 Positive effects were seen in dyslipidemia and obese patients 
when prescribed atorvastatin combined with metformin compared 
with atorvastatin monotherapy in lowering the rate of obesity and 
subclinical inflammation [34]. Metformin use also showed positive 
cardiovascular effects in female patients with symptomatic myocar-
dial ischemia [35], in women with polycystic ovary syndrome [36], 
and in patients with peripheral arterial disease [37]. Mohan et al., also 
showed that metformin reduced Left Ventricular (LV) mass indexed 
to height, improved Systolic Blood Pressure (SBP), reduced oxidative 
stress and reduced measures of obesity in patients with CAD [38]. 
Conversely, a more recent study showed no effects on several markers 
of CVD for patients without diabetes but with high cardiovascular risk 
[39]. Despite these findings, studies trialing metformin in populations 
with established CVD have little relevance to primary prevention of 
CVD due to the cumulative effect of lifestyle factors from a young 
age that impact on CVD risk in adulthood [40-42] and the compara-
tively short duration of the trial. The pilot placebo-controlled study of 
women without diabetes showed that, besides improving variables of 
vascular function, metformin also improved measures taken during an 
exercise tolerance test: maximal ST-segment depression, Duke Score 
and chest-pain incidence [35]. These findings stressed the importance 
of metformin use as an additional therapy to reduce cardiovascular 
risk factors [43]. Further research is required to establish the impact 
of metformin on CVD risk in those without diabetes [39].
Definition of Ageing in General Practice
 There are different personal, cultural and societal perspectives on 
parameters constituting ‘ageing’ and elderly. Chronological age for 
older adults in the USA is age ≥ 65 years, whereas in Europe and other 
parts of the world, it is 60 years and older. Generally accepted biolog-
ical definitions of ageing include ‘the reduced capacity to regenerate 
damaged tissue’ [44] and ‘a deficit in maintaining homeostatic pro-
cesses over time, leading to functional decline and increased risk for 
disease and death’ [45]. Ageing, insulin resistance and inflammation 
are associated with the pathogenesis of non-communicable diseases 
including T2DM [46], CVD [47], cancer [48], depression [49], de-
mentia [50] and frailty [51], a condition of increased vulnerability 
and adverse health outcomes. The prognosis of an elderly with mul-
tiple comorbidity is poor due to functional, psychological and social 
issues. As our society has a rising elderly population, there is growing 
interest for research addressing interventions beyond healthy lifestyle 
to extend the number of functional years.
Age-dependent (physiological ageing) and age-related 
diseases (pathological ageing) in healthy ageing
 In order to better understand the healthy ageing process and how to 
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invest in it, it is important to highlight the difference between age-de-
pendent and age-related diseases. Age-dependent diseases include 
CAD, cerebrovascular disease, T2DM, osteoporosis and Alzheimer’s 
disease. Its pathogenesis appears to involve physiological ageing pro-
cesses, chronic damage from inflammation [52] and metabolic syn-
drome [53]. Mortality and morbidity in these diseases increase expo-
nentially with advanced age. In contrast, age-related diseases have a 
temporal relationship with age and are not necessarily related to the 
physiological ageing process. A recent review [54] raised the debate 
on whether ageing is a disease in itself, suggesting that physiological 
ageing is indistinguishable from pathology [55] whereas other studies 
argue that ageing differs from age-related diseases and other pathol-
ogies [56,57]. The answer to this question will have important theo-
retical and practical consequences with various interventions capable 
of decelerating the ageing process [58,59]. If ageing is treated as a 
disease, treatment and intervention including lifestyle modifications, 
drugs and medical treatments that counteract the mechanisms of age-
ing may delay frailty for decades, ideally until the apparent inevitable 
limit of human lifespan is reached [60]. The more radical approach is 
to rejuvenate human tissues, organs, and whole body in order to over-
take the above-mentioned limits of human lifespan [60]. 
Mechanism of ageing
 The process of ageing is complex and multifactorial. Indeed, phys-
iological and evolutionary theories have been suggested in order to 
deduce the mechanisms of ageing [61]. DNA damage is one such 
mechanism that has received the most attention in order to identify 
pathways that can be contained or modified to halt or delay ageing 
itself. Endogenous sources for DNA damage include Reactive Ox-
ygen Species (ROS), alkylation and hydrolysis, whereas exogenous 
sources include chemicals, Ultraviolet (UV) and other forms of radi-
ation [62]. Oxidative stress, a process where free radicals cause DNA 
damage and impairment in proteins and lipids translation, provides 
another mechanism of ageing via genetic damage [63]. Most ageing 
research comes from animal experiments attempting to expand lifes-
pan. Indeed, a novel CRISPR/Cas9 genome-editing therapy that can 
suppress the accelerated ageing observed in mice with Hutchison-Gil-
ford progeria syndrome, a rare genetic disorder that also afflicts hu-
mans, has been put forward. This treatment provides important in-
sight into new molecular pathways involved in accelerated ageing, as 
well as how to reduce toxins via gene therapy [64].
 The evolutionary theory of ageing assumes a linear increase in 
mutations over time whilst ageing and death are initially circumvent-
ed by cellular redundancy mechanisms [65], as mutations overwhelm 
the system with ineffective protein translation resulting in ageing. 
From the cellular level, this leads to organ dysfunction, causing di-
abetes, cardiovascular diseases, neurodegenerative diseases, chronic 
inflammatory diseases leading to early frailty, delirium and falls, indi-
cated that ageing and pathologies share the same common mechanism 
[54]. 
The impact of metformin on mechanisms related to the 
ageing process
 The mechanisms by which metformin impact on glucose homeo-
stasis includes the non-competitive inhibition of the mitochondrial 
glycerophosphate dehydrogenase enzyme, which alters hepatocel-
lular redox state, thus reducing the conversion of lactate and glyc-
erol to glucose, decreasing hepatic gluconeogenesis [66], altering 
mechanisms related to ageing. Furthermore, it has been well docu-
mented that metformin mildly reduces levels of High-Sensitivity 
C-Reactive Protein (hsCRP) [67], and improves endothelial function 
[68,69], enhancing the benefits against the ageing process. Anti-di-
abetic activity of metformin may be potentiated via action on the 
enterocytes and enteroendocrine cells [70]. Metformin has been im-
plicated as the antagonist of the gut hormone Glucagon-Like with 
Peptide-1 (GLP-1) in patients with T2DM [71]. In addition to GLP-1, 
two other hormones including Peptide YY (PYY) and Growth/Differ-
entiation Factor 15 (GDF15) are increased significantly on metformin 
therapy, GDF15 being produced mainly in the intestine via the “inte-
grated stress response” [72]. GDF15 was positively associated with 
the incidence of diabetes mellitus in the longitudinal Malmo Diet and 
Cancer-Cardiovascular cohort [73]. Metformin exerts its anti-diabetic 
effects by increasing the activity of Adenosine Monophosphate-Acti-
vated Protein Kinase (AMPK) and mediating the mitochondrial com-
plex I receptor for the anti-diabetic action of metformin [74].
Psychological health including depression and anxiety
 A placebo-controlled Chinese study by Guo et al., with participants 
with T2DM and mild to moderate depression, showed metformin im-
proved depressive symptoms, possibly related to better glycemic con-
trol [75]. The outcome of this study is clinically relevant for clinician 
to be proactive in view of high prevalence of depression in the elderly 
with or without diabetes. Another case-control study in China exam-
ining elderly patients with diabetes using geriatric depression scale 
concluded that overweight status, poor physical capabilities and low 
activity level, and the presence of more than two additional illnesses 
were risk factors for depression, and metformin was a protective fac-
tor against depression in elderly patients with diabetes [76]. In light 
of the anti-depressive effects of metformin in the Chinese population, 
it will be prudent to examine whether metformin will have similar 
effects in the western population or different cultural groups.
 There is no direct evidence in human regarding the effects of met-
formin on anxiety. An interesting mice study suggest that metformin 
may act by decreasing circulating Branched-Chain Amino Acids 
(BCAAs) levels to favour serotonergic neurotransmission in the hip-
pocampus and promote anti-anxiety effects in mice fed a High-Fat 
Diet (HFD) [77]. These findings can potentially translate into clinical 
practice that a diet poor in BCAAs with metformin use or as add-
on therapy to conventional anti-anxiety drugs could help to relieve 
anxiety symptoms in patients with metabolic comorbidities. It will 
be interesting to explore whether there is any role of metformin in 
relieving anxiety symptoms in the elderly as part of healthy ageing 
coping strategies.
Mild cognitive impairment and dementia
 Metformin has been shown in many observational studies to lead 
to reductions in Mild Cognitive Impairment (MCI) [78] and demen-
tia [79,80] among participants with diabetes taking metformin when 
compared with no medication or other glucose-lowering agents. A 
study in Taiwanese individuals aged ≥ 50 years showed that met-
formin use significantly decreased the risk of dementia compared 
with no medication (Hazard Ratio [HR] 0.76 [95% Confidence In-
terval {CI} 0.58-0.98]) [75]. Another evaluation study examined data 
from 365 individuals from the Singapore Longitudinal Ageing Study 
(aged ≥ 55 years) to demonstrate that metformin use was associated 
with lower risk of MCI (Odds Ratio [OR] 0.49 [CI 0.25, 0.95]) [79]. 
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Another study from Taiwan used an insurance database from 67,731 
individuals and found that dementia risk was lower in those taking 
metformin compared with other glucose-lowering medications [80]. 
It is essential to be aware of the limitations of confounding factors 
influencing the outcome interpretation of these studies. Despite of 
the limitations in these studies, a recent clinical trial substantiated 
the above evidence by showing that metformin improved cognition 
in individuals without Diabetes [81]. Eighty amnestic MCI partici-
pants (aged 55 to 90 years) without treated diabetes were randomly 
assigned to metformin or placebo for 12 months’ follow-up. Partici-
pants on the metformin arm showed improvements in the selective 
reminding test, even after adjusting for baseline values for the Alz-
heimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) 
score. A recent retrospective cohort study suggested that metformin 
use in T2DM patients was associated with a significantly lower risk of 
dementia, especially after use for more than two years [82]. The risk 
reduction showed a dose-response pattern, was consistent in sensitiv-
ity analyses and was not affected by the year of enrollment.
 In contrast, an Australian clinical study showed that participants 
with diabetes (n=126, including 35 metformin users and 91 non-us-
ers) displayed worse cognitive performance in the metformin group 
(OR 2.23, 95% CI 1.05-4.75) [83]. The finding was in consistent with 
later evidence that metformin may be associated with deleterious ef-
fects on cognitive function in the elderly [84]. Researchers in mouse 
models of ageing reported worsening tau aggregation (causing neuro-
fibrillary degeneration and neurotoxicity associated with the develop-
ment of Alzheimer’s disease) and abnormal behavior [85] or impaired 
spatial memory and visual acuity [86]. Furthermore, a recent analy-
sis of patients’ cognitive function 8-10 years after metformin use did 
not support any benefit of metformin use [87]. The most recent study 
showed that metformin is associated with a higher risk of vitamin B12 
and vitamin B6 deficiency, leading to an increased risk of cognitive 
dysfunction [88]. Thus, vitamin supplementation is strongly recom-
mended to metformin users.
 In summary, although there have been extensive research and clin-
ical trials involving metformin in patients with diabetes, inconsistent 
dementia risk and cognitive function results warrant more in-depth 
research. Metformin is relatively safe and would not cause hypogly-
cemia when used as monotherapy. However, its clinical impact on 
the prevention of dementia in individuals with and without diabetes 
warrants a large RCT as part of the healthy ageing strategies.
Future Developments in Metformin Research
 One of the priorities to reduce healthcare costs in an ageing soci-
ety is to delay the onset of frailty by identifying risk factors such as 
cardiovascular and musculoskeletal diseases in the pre-frailty stage. 
It is well documented that lifestyle modifications including diverse 
exercise interventions have several advantages with the challenge of 
adherence over time [89]. Metformin offers a cost-effective alterna-
tive besides controlling diabetes or reducing its risk, improving mood 
and cognitive and physical function. Metformin’s “off-label” use 
alone or in combination with other anti-diabetics gains popularity for 
effective prevention of diabetes [90] as well as for management of 
metabolic syndrome, obesity and polycystic ovarian disease [91,92]. 
The TAME trial primary endpoints comprise the incidence of MI, 
congestive heart failure, stroke, most cancers, dementia, and death, 
but not diabetes and frailty. A clinical trial by Espinoza et al. provides 
arguments that frailty may be an important endpoint [93]. TAME plans 
to randomize 3,000 older persons aged between 65-79 years without 
diabetes including persons with chronic diseases [94] and most likely 
only persons with impaired glucose tolerance/fasting hyperglycemia. 
In addition, the TAME biomarker sub-study includes blood-based 
biomarkers including interleukin- 6, C-reactive protein, insulin-like 
growth factor 1, insulin, cystatin C, N-terminal prohormone of brain 
natriuretic peptide, HbA1c, and GDF15, but not GLP-1 [95]. The bio-
marker workgroup raised important mechanism questions from basic 
science points of view for TAME and other trials including cancer 
or neurological diseases impacted by metformin use, in which met-
formin increases the activity of AMPK and may stimulate autophagy 
[96-98] or modulate it in leukocytes of T2DM patients [99]. Similar 
to the pharmaceutical system in the United States, metformin can be 
listed on our Australian Pharmaceutical Benefits Scheme (PBS) sys-
tem for the novel indications if the research proves its efficacy. There 
is also plan from the TAME researchers to “repurpose” metformin 
for increasing lists of disease indications in mice and humans with 
advancing age [100,101]. The TAME trial has been listed in Clinical-
Trials.gov as of November 2019 and the study protocol is now in the 
public domain.
 Another large clinical trial sponsored by the Veterans Adminis-
tration (NCT02915198; VA-IMPACT) started on February 19, 2019. 
This trial plans to study 7,868 subjects with prediabetes and estab-
lished atherosclerotic disease for 4.5 years in a double-blind place-
bo control trial with metformin extended release versus placebo for 
a combined primary endpoints. The primary endpoints include the 
time to death from any cause, MI, stroke, hospitalization for unstable 
angina, or symptom-driven coronary revascularization, while time-
to-events for oncology-related diseases and diabetes are secondary 
endpoints.
 A recent double blind, randomized Glucose Lowering in Non-Di-
abetic Hyperglycaemia Trial (GLINT) testing the feasibility of met-
formin reducing the risk of cancer in elderly obese patients with a high 
risk of CVD and non-diabetic hyperglycemia concluded that 20,000 
subjects are required to obtain significant results for only CVD [102]. 
Metformin in Longevity Study (MILES) was a small, double-blind, 
placebo-controlled crossover trial in which they investigated differ-
entially expressed genes in muscular and adipose tissue biopsies after 
6-week administration of placebo or 1.5 g per day of metformin [103]. 
The study reported biomarkers (such as interleukin-6, C-reactive pro-
tein, tumour necrosis factor α, insulin-like growth factor 1, cystatin C, 
N-terminal B-type natriuretic peptides and haemoglobin A1c) select-
ed by the TAME working group except GDF15 [95]. Early Prevention 
of Diabetes Complications in Europe (ePREDICE) is another large 
multicenter RCT and currently recruiting participants mostly in Eu-
rope, evaluating the impact of metformin (compared with a dipeptidyl 
peptidase-4 inhibitor) on microvascular complications and cognitive 
function in individuals with non-diabetic intermediate hyperglycae-
mia [104].
 Taken together, metformin has been identified as a potential agent 
for primary prevention of cardiovascular diseases and reduction in 
Major Adverse Cardiovascular Events (MACE) and mortality in low 
cardiovascular risk and healthy individual (Table 1).
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Conclusion and Clinical Perspectives
 The rationale for the ongoing or planned metformin trials is almost 
exclusively based on observations of potential benefits in a population 
with diabetes (or prediabetes). Beyond its impact on diabetic control, 
metformin has diverse ranges of effects targeting multiple age-related 
mechanisms. Cellular and animal studies have found that metformin 
reduces insulin resistance and decreases inflammatory markers, NF-
κB, ROS and mTOR pathways, thus decreasing DNA damage. Hu-
man observational studies have shown that metformin decreases the 
risk of CVD, cancer, depression and other age-related conditions. A 
few studies found that metformin may reduce MCI and dementia. On-
going randomized clinical trials will evaluate whether metformin can 
decrease death from any cause, CVD, stroke, prevent or delay the de-
velopment of age-dependent diseases, and improve physical and cog-
nitive function. Given its known safety and long-term use in humans, 
metformin could become a pharmacological intervention against 
multi-morbidity, frailty and ageing in individuals with or without 
diabetes, especially in people with low cardiovascular risks or healthy 
elderly in the primary prevention trial. In terms of primary prevention 
trial, the Aspirin in Reducing Events in the Elderly (ASPREE) was a 
primary prevention trial that was established to investigate whether 
the daily use of 100 mg of enteric-coated aspirin would prolong the 
healthy life span of older adults conducted in Australia and the United 
States, recruiting 19,114 relatively healthy older persons from com-
munity settings. The primary end point was disability-free survival, 
which was defined as survival free from dementia or persistent physi-
cal disability. The primary composite end point was derived from the 
first end-point events of death, dementia and persistent physical dis-
ability. The use of low-dose aspirin did not differ significantly from 
placebo in influencing the rate of the primary end point after a median 
of 4.7 years of follow-up [105]. Taking together, metformin will have 
great potential to play an important healthy ageing role in combating 
cardiovascular risks and prolonging disability-free survival. Hence, a 
properly designed clinical trial similar to the ASPREE trial involving 
metformin use in the healthy population will most likely answer the 
challenges of healthy ageing in our modern society.
Author and 
Year Design Target population and size Outcomes measured
Follow up 
time Summary of findings
Orio et al., [36]
Prospective, 
baseline-con-
trolled trial
N=30
Young women with PCOS 
without additional metabolic or 
CV disease
Complete hormone profile, serum insulin, 
glucose, lipid and endothelin-1. Brachial 
artery diameter and cIMT
6 months
6-month course of metformin improves 
endothelial structure and function in young, 
normal-weight women with PCOS.
Khan et al., 
[37]
Retrospective 
cohort study
N=1204
Patients who underwent 
revascularization for chronic 
limb ischemia
Primary patency, secondary patency, limb 
salvage, major adverse limb events, major 
adverse cardiac events and survival rates
Mean of 48 
months
Metformin is associated with improved survival 
and decreased incidence of adverse cardiac 
events in PAD patients. It did not have an impact 
on patency or limb salvage rates.
Preiss et al., 
[39]
Double-blind, 
placebo-con-
trolled trial
N=173
Patients taking statins, without 
T2DM with coronary heart 
disease and large WC
Mean distal cIMT, carotid plaque score, 
glucose, lipids, C-reactive protein and tissue 
plasminogen activator
18 months
Metformin had no effect on cIMT and little or no 
effect on several surrogate markers of cardiovas-
cular disease in non-diabetic patients with high 
cardiovascular risk, taking statins.
Mohan et al., 
[38]
Double-blind, 
placebo-con-
trolled trial
N=63
Patients without diabetes who 
have CAD with insulin resis-
tance and/or prediabetes
LV mass indexed to height, LV ejection frac-
tion, mass, and volume; abdominal obesity, 
glycaemic parameters, endothelial function, 
and blood biomarkers
12 months
Metformin treatment significantly reduced LV 
mass indexed to height and LV mass compared 
with placebo in patients with CAD without 
T2DM. It also improved SBP, reduced oxidative 
stress and reduced measures of obesity.
Lexis et al., 
[32]
Double-blind, 
placebo-con-
trolled trial
N=379
Patients who underwent 
primary percutaneous coronary 
intervention for STEMI
LV ejection fraction, NT-proBNP, major 
adverse cardiac events 4 months
Metformin compared with placebo did not result 
in improved LV ejection fraction or NT-proBNP 
levels. As LV function is an important predictor 
of morbidity and mortality after STEMI, it is 
unlikely that metformin will have a significant 
effect on long-term outcomes.
Hartman et al., 
(2 year follow 
up of Lexis et 
al.,) [33]
Double-blind, 
placebo-con-
trolled trial
N=379 Patients who underwent 
primary percutaneous coronary 
intervention for STEMI
Major adverse cardiac events, NT-proBNP, 
death, reinfarction, recurrent coronary inter-
vention, stroke, heart failure, ICD implanta-
tion, and new-onset diabetes mellitus
24 months
Four months metformin treatment initiated at 
the time of hospitalization in STEMI patients 
without diabetes did not exert beneficial long-
term effects
Knowler et 
al., [9]
Randomized 
clinical trial
N=3234 Non-diabetic persons 
with elevated fasting and 
post-load plasma glucose 
concentrations
Diabetes (glucose), adverse effects Mean of 34 months
Lifestyle changes and treatment with metformin 
both reduced the incidence of diabetes in persons 
at high risk. The lifestyle intervention was more 
effective than metformin.
Kulkarni et al., 
[103]
Double-blind, 
placebo-con-
trolled, Crossover 
trial
N=14 Older patients with 
impaired glucose tolerance but 
no diabetes.
Skeletal muscle and subcutaneous adipose 
tissue for number of expressed genes. Serum 
glucose, insulin,
3 months
6 weeks of metformin can improve age-associat-
ed metabolic derangements in glucose intolerant 
older adults. Metformin has metabolic and 
nonmetabolic effects linked to aging
Luchsinger et 
al., [81]
Double-blind pla-
cebo-controlled 
randomized pilot 
trial
N=80 Patients with aMCI, 
overweight or obese, without 
treated diabetes
Bushcke SRT, ADAS-cog, plasma Aβ42, 
relative glucose uptake in the posterior 
cingulate-precuneus measured by brain FDG 
PET and MRI
12 months
Preliminary evidence of efficacy to improve SRT 
but not ADASCog. A larger trial seems warrant-
ed to evaluate the efficacy and cognitive safety of 
metformin in prodromal Alzheimer's disease
Table 1: Summary of clinical trials with metformin in non-diabetic population.
PCOS, Polycystic Ovary Syndrome; CV, Cardiovascular; cIMT, Carotid Intima-Media Thickness; PAD, Peripheral Arterial Disease; T2DM, Type 2 Diabetes Mellitus; WC, Waist 
Circumference; CAD, Coronary Arterial Disease; LV, Left Ventricular; SBP, Systolic Blood Pressure; STEMI, ST-Elevation Myocardial Infarction; NT-proBNP, N-Terminal Pro-
Brain Natriuretic Peptide; ICD, Implantable Cardioverter-Defibrillator; aMCI, Amnestic Mild Cognitive Impairment; SRT, Selective Reminding Test; ADAS-cog, Alzheimer’s 
Disease Assessment Scale Cognitive Subscale; Aβ42, Amyloid Beta 42; FDG, F-labelled 2-Deoxy-2-fluoro-D-Glucose; PET, Positron Emission Tomography; MRI, Magnetic 
Resonance Imaging.
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